Drug details

Sutent (sunitinib malate)

type of Antineoplastic Tyrosine Kinase Inhibitors, Antineoplastics, VEGF Inhibitor

Sutent (sunitinib malate) is a multi-kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor after disease progression on, or intolerance to imatinib mesylate, for advanced renal cell carcinoma, and for progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable, locally advanced or metastatic disease. Sutent is available in generic form.

This drug may have the following side effects:

• weakness
  
• shortness of breath
  
• nausea
  
• vomiting
  
• Diarrhea
  
• cough
  
• fatigue
  
• unusual or unpleasant taste in the mouth
• upset stomach
  
• constipation
  
• dry skin
  
• changes in skin or hair color (yellow skin or lighter skin/hair)
  
• hair loss
  
• joint pain
  
• back pain
  
• tiredness
  
• fever
  
• mouth pain/sores
  
• abdominal pain
  
• rash or other skin changes such as dry or cracked skin
  
• blisters or rash on hands or feet
  
• loss of appetite
  
• pain or swelling in the arms or legs
  
• numbness or tingling of the arms or legs
  
• bleeding
  
• watery eyes
  
• swelling around the eyes
  
• chest pain
  
• general ill feeling, or
• uneven heart rate.

The following drugs are related to Sutent, either as a replacement or used together:

• Afinitor (everolimus tablets)
• Proleukin (aldesleukin for injection)
• Cabometyx (cabozantinib tablets)
• Exkivity (mobocertinib capsules)
• Sancuso (granisetron transdermal system)